| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic Laboratories’ definitive testing approach utilizes mass spectrometry technology to accurately identify parent drugs and metabolites of substances, which, because of complex metabolic processes, similar chemical structures, and pharmaceutical impurities, could interfere with the results of immunoassay screening. Our fast and cost-effective definitive tests are available in a variety of configurations, including individually, for each drug of abuse class.
Our approach gives providers the flexibility to perform immunoassays locally while enabling confidence through confirmatory testing. Quantitative results from individual drug confirmations can be useful for managing complex cases, including instances where testing results are questioned or denied. Test reports identify specific drug findings and their concentrations.
Confirmatory testing menu
Opiates
Semi-synthetics
Synthetics
Alcohol
Barbiturates
Benzodiazepines
Highlights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
Amphetamine-type stimulants
Cocaine
Methylphenidate (Ritalin)
Nicotine
Highlights
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.
Marijuana (THC)
Phencyclidine (PCP)
Highlights
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.